Healthcare - Biotechnology - NASDAQ - US
$ 8.83
10.1 %
$ 408 M
Market Cap
-3.94
P/E
CASH FLOW STATEMENT
-75.8 M
OPERATING CASH FLOW
116 M
INVESTING CASH FLOW
157 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
4D Molecular Therapeutics, Inc.
| Net Income | -101 M |
| Depreciation & Amortization | 5.75 M |
| Capital Expenditures | -2.77 M |
| Stock-Based Compensation | 19.7 M |
| Change in Working Capital | 630 K |
| Others | -1.26 M |
| Free Cash Flow | -78.6 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (100.8) | (107.5) | (71.3) | (56.7) | (49.3) | (9.6) | (11.2) |
| Depreciation & Amortization | 5.7 | 3.9 | 3.0 | 1.4 | 1.0 | 0.7 | 0.6 |
| Deferred Income Tax | 0 | 0 | 0 | 20 K | 2.7 | 0 | 0 |
| Stock Based Compensation | 19.7 | 17.1 | 13.8 | 5.0 | 3.5 | 1.4 | 0.3 |
| Other Operating Activities | (1.0) | 1.1 | 0.9 | 48 K | 5.1 | 2 K | 39 K |
| Change in Working Capital | 0.6 | (1.3) | (15.5) | (0.7) | 0.3 | (8.8) | 18.5 |
| Cash From Operations | (75.8) | (86.7) | (69.1) | (50.9) | (36.7) | (16.3) | 8.2 |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | (2.8) | (11.5) | (9.1) | (1.0) | (3.2) | (0.4) | (0.6) |
| Other Items | 118.5 | (5.5) | (163.6) | 0 | 0 | 0 | 8.2 |
| Cash From Investing Activities | 115.7 | (17.1) | (172.7) | (1.0) | (3.2) | (0.4) | 7.7 |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (2.3) | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 8.5 | 3.1 | 3.8 | 73.3 | 10 K | 169.0 | 0 |
| Cash From Financing Activities | 156.8 | 3.1 | 118.1 | 279.0 | (2.2) | 84.6 | 16 K |
| CHANGE IN CASH | |||||||
| Net Change In Cash | 196.8 | (100.7) | (123.7) | 227.1 | (42.1) | 67.9 | 15.9 |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (78.6) | (98.2) | (78.2) | (51.9) | (39.9) | (16.7) | 7.7 |